Drugs / Human erythropoietin
Human erythropoietin
also known as
Human Erythropoietin Injection · EPIAO · EPO · epoetin alfa · recombinant human erythropoietin
Protein / enzyme biologic targets EPOR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable3 trials | ||||||
| — | NCT06012760 | Jan 2025 → Jan 2028 expected | iron deficiency anemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05911438 | Jul 2023 → Dec 2024 | — | West China Hospital | Unknown | No outcome recorded |
| — | NCT05857891 | May 2023 → Oct 2026 expected | acute respiratory distress syndrome | Second Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05629598 Comparator | Apr 2022 → Mar 2023 | anemia | Angde Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human erythropoietin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06012760 ↗ |
| Known as | EPIAO | “Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.” NCT05911438 ↗ |
| Known as | EPO | “Erythropoietin (EPO), also known as erythrocyte- stimulating factor, erythropoietin, has a certain amount in normal human body” NCT05857891 ↗ |
| Known as | epoetin alfa | “We hypothesized that therapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfusions.” PMID 17804841 ↗ Sep 2007 |
| Known as | Human Erythropoietin Injection | “Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.” NCT05911438 ↗1“Human Erythropoietin Injection at a dosage of 150 IU per kilogram” NCT06012760 ↗ |
| Known as | recombinant human erythropoietin | “We hypothesized that therapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfusions.” PMID 17804841 ↗ Sep 2007 |
| Modality | Protein / enzyme biologic | “Biological: Human erythropoietin injection” NCT05629598 ↗ |
| Route | Subcutaneous | “subcutaneous recombinant human erythropoietin (150 IU/kg)” NCT06012760 ↗ |
| Target | EPOR | “Fas- and neutrophil-mediated apoptosis of A549 and NHBE cells was inhibited by rhEPO by a specific EPO-EPOR-mediated mechanism.” PMID 19164355 ↗ Jan 2009 |